Thanks PoS,
I was thinking that its not only investors who might be having trouble adjusting to the new paradigm of Phylogica as a global leader.
A deal in February may not have been as lucrative as a deal in April. I don't think the analogy of a bird in the hand applies when the technology is attracting world-wide attention.
In the brave new world of intracellular drug delivery the economics of licencing FPPs might be growing in value. With $6m in the bank and Hopkins running the show, I'm happy to wait.
global leader, page-4
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $793.2M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 17.3¢ | 16.5¢ | $137.0K | 809.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 534693 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 68320 | 3 |
View Market Depth
| Last trade - 15.31pm 08/10/2024 (20 minute delay) ? |
| PYC (ASX) Chart |